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Six Sigma methodology has been successfully applied to daily operations by several leading global private firms including GE and
Motorola, to leverage their net profits. Comparatively, limited studies have been conducted to find outwhether this highly successful
methodology can be applied to research and development (R&D). In the current study, we have reviewed and proposed a process
for a probable integration of Six Sigma methodology to large-scale production of Penicillin G and its subsequent conversion to
6-aminopenicillanic acid (6-APA). It is anticipated that the important aspects of quality control and quality assurance will highly
benefit from the integration of Six Sigma methodology in mass production of Penicillin G and/or its conversion to 6-APA.
1. Introduction
Out of any other entities in the world of pharmaceuticals,
perhaps Penicillin needs no introduction. Right from the
time of World War II, Penicillin, the first discovered 𝛽-
lactam antibiotic (𝛽LA), has been and still is one of the
most widely used antibiotic agents, in terms of annual bulk
production (∼3 × 107 kg/year), annual sales (∼$15 billion),
and market share (∼65% of the total antibiotic market)
[1–3]. It is no secret that the growth of many penicillin-
resistant pathogens has prompted only a minor portion of
penicillins to be utilized for therapeutic functions [4]. On
the other hand, the majority are used as precursors for
manufacturing semisynthetic penicillins (SSPs). This further
boosts the effectiveness of penicillins and also widens the
range of antimicrobial properties or activities [2, 5].
Production of SSPs is essentially a two-step process: first,
penicillins (in bulk) are converted to 6-aminopenicillanic
acid (6-APA) through a procedure mediated through chem-
icals or enzymes. Next, extended processing of 6-APA is
achieved by using enzymes to get the final product (SSPs)
[6]. Conventionally, 6-APA used to be synthesized prin-
cipally by hydrolysis of penicillins using unsafe chemicals
and solvents (trimethylchlorosilane, phosphorous pentachlo-
ride, and dichloromethane), at unusually low temperatures
[6]. Currently, the preferred method for this is enzymatic
alteration of bulk penicillins into 6-APA using penicillin
acylase [4]. In the context of the current work, we will
focus only on Penicillin G acylase (PGA). It is interesting to
note that till date several stages for enhanced heterologous
production of PGA have been proposed using recombinant
DNA technology and for this Escherichia coli or E. coli is
the preferred host system due to strong growth features and
renowned physiology and metabolism [4]. Out of several
different microbial PGA sources, PGA from E. coli (EcPGA)
has outstanding potential for industrial purposes and also has
been broadly studied as a part of academic research [7, 8].
Research focus on PGA production involving expression of
“pac” gene from E. coli in E. coli has transcended diverse
but linked areas like manipulation of the cell physiology
[9–11], investigation of the effects of translocation efficiency
[10, 11], and extracellular secretion [12, 13]. In addition, several
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studies have focused on expression of “pac” genes from other
bacterial sources inE. coli. For a detailed review see the review
by Srirangan et al. [4]. Along with E. coli, alternative hosts
for expression have also been investigated: Gram positive
Bacillus expression systems [14–17] and eukaryotic expression
systems like Saccharomyces cerevisiae and Pichia pastoris [18–
20].
Contrary to laboratory scale, production of PGA in
large scales is challenging mainly due to this exclusive
gene expression and various methods for protein maturation
[4]. Therefore, it is mandatory to design key biochemical
engineering approaches with improved upstream processing
(strain manipulation), cultivation method, and highly robust
downstream processing (DSP). The most important aspect
that needs focus is the downstream processing with chro-
matography as an essential tool for PGA recuperation and
refinement [21–24], direct immobilization without purifica-
tion [25], and selective yield of the periplasmic part only and
not the whole cell lysate [26, 27]. Very recently, a signifi-
cant advancement has been achieved through extracellular
production of PGA with high purity and yield has been
reported in E. coli involving a single-step DSP which is
based on tangential flowfiltration anion-exchangemembrane
chromatography (TFF-AMEC) [28]. All these highlight the
importance of application of a total quality system that needs
to be built-in into the system rather than tested only on the
end-products. It is our belief that all the distinct stages like
strainmanipulation, cultivationmethod, and purification can
be significantly improved by implementing a quality control
scheme by identifying the critical control points. Past study
from our group has shown that a stringent quality system
may be proposed for a general pilot scale production of
any alternative and complementary medicine [29]. With this
motivation we have analyzed and proposed a mechanism for
inclusion of Six Sigma methodology in the production pro-
cess. This may reduce batch-to-batch variations and produce
better products that will adhere to the regulatory norms and
meet quality issues.
2. Recent Progress in Enzymatic
Transformation of Penicillin G to 6-APA
Enzymatic hydrolysis of Penicillin G to obtain 6-APA is one
of the most relevant examples of industrial implementation
of biocatalysts [1, 31, 32]. 6-APA is the main precursor for
the production of semisynthetic𝛽-lactamic antibiotics [31]. A
procedure for large-scale industrial production of Penicillin
G is represented in Figure 1. 6-APA is produced at the scale
of about 10,000 tons per year [33]. It has been reported
that organic solvent mediated hydrolysis of Penicillin G,
with the objective of extracting it from the culture medium,
may greatly abridge the industrial manufacturing of 6-APA
[34]. It may be noted that immobilization of enzyme on a
carrier results in the loss of enzyme activity [35]. Therefore,
in recent years, carrier-free immobilized enzymes such as
cross-linked enzymes, cross-linked enzyme crystals (CLECs),
and cross-linked enzyme aggregates (CLEAs) have been
in regular use [36]. These procedures are beneficial over
carrier-bound enzymes as the final preparation has high
concentration of enzyme per unit volume [35]. Optimization
of 6-APA manufacturing using cross-linked enzyme aggre-
gates (CLEA) of Bacillus badius Penicillin G acylase (PAC)
has also been reported [35]. According to the authors, this
work has a strong potential for industrial application mainly
because of faster conversion of Penicillin G to 6-APA by
CLEA-PAC and also proficient reusability.
In a recent study, the enzymatic hydrolysis of Penicillin
G for production of 6-APA was obtained by using Penicillin
G acylase as catalyst in an aqueous-methyl isobutyl ketone
(MIBK) system. According to the authors, the optimized
conditions are initial pH 8.0, 5.0% (W = V) substrate
(Penicillin G), temperature at 35∘C, and the ratio of aqueous
and organic phase 3 : 1 [33]. In a very recent study, different
soil bacterial samples from different places of Dibrugarh
(India) were isolated and incubated in presence of Penicillin
G (2mg/mL) for 48 hours at 37∘C for conversion to 6-APA
which was detected by thin layer chromatography (TLC)
[37]. Also, the use of whole cell or isolated enzyme for the
preparation of 6-APA has been reported [35, 38, 39]. This
includes manufacturing of a fully efficient, permuted single-
chain Penicillin G acylase [38], production of Alcaligenes fae-
calis Penicillin G acylase in Bacillus subtilis WB600 (pMA5)
fed with partially hydrolyzed starch [39], and application of
cross-linked enzyme aggregates of Bacillus badius Penicillin
G acylase for the production of 6-APA [35]. In order to
preserve high activity and specificity, better contamination
control, and log life, various techniques have been used to
immobilize the Penicillin G acylase either as free form or as
whole cell enzyme [40]. However, itmay be noted that further
studies would benefit from optimizing the manufacturing of
6-APA using different immobilization techniques [37]. In the
context of the current work, considering several options, we
choose to base our hypothesis based on a recombinant E. coli
based expression platform that must contain the “pac” gene
fromE. coli itself. Considering that once the upstreamprocess
is optimized, cultivation should be done with a high cell
density and should be followed by extensiveDSP, as suggested
elsewhere [4, 34].
3. 6-APA: Precursor for Semisynthesis of
𝛽-Lactam Antibiotics
In pharmaceutical industries, 6-aminopenicillanic acid (6-
APA) is a very important intermediate product, primarily
for being the precursor for the semisynthesis of 𝛽-lactam
antibiotics [35] such as ampicillin and amoxicillin. Penicillin
acylase is an enzyme produced by several bacteria and fungi.
Although its metabolic role is not completely understood, it
is widely used for the production of 6-APA.The main reason
is that it can catalyze the hydrolysis of Penicillin G in this
compound andphenylacetic acid [41].This enzyme could also
be used to catalyze the reverse reaction and the synthesis of
the amide bond.
3.1. Mechanism of Action of Penicillin Acylase. 6-APA is an
integral 𝛽-lactam compound of various penicillins. Peni-
cillins have a heterocyclic group consisting of a thiazolidine
ring (with 5 members including one sulphur atom) joined
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Figure 1: Schematic representation for large-scale production of Penicillin G (reproduced and redrawn from elsewhere [30]). Steps are self-
explanatory. For a detailed account, see the source [30]. “OUR”: oxygen uptake rate, “OTR”: oxygen transfer rate, “MCB”: master cell bank,
and “MWCB”: manufacturer’s working cell bank.
with a 𝛽-lactam ring (with 4 members). These are distin-
guished fromeach other by the nature of the side chain, which
is attached to the amine group in position 6 through a peptide
link [42]. The fermentation of microbes of the Penicillium
chrysogenum type makes it possible to obtain the greatest
output of the corresponding penicillin. But there must be
optimum culture conditions depending on the precursor
used,which is normally PenGorPenV. Several other reactions
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also take place during this type of fermentation and alongside
the penicillin biosynthesis reactions. By other reactions, we
refer to the reactions forming othermetabolites, as well as the
degradation reactions of penicillin to penicillanic acid. They
also include oxidation of the phenylacetic acid precursor to
o-hydroxyphenylacetic acid (oxidized derivative). All these
reactions must be controlled.
The resulting penicillin is converted into 6-APA by the
reaction of removing the side chain linked to the amino
group in position 6. Initially chemical processes achieved
this reaction, but in recent times it is carried out through
enzymatic processes using enzymes like penicillin acylase or
amidase. The function of this enzyme is to recognize the
side chain and break the peptide link joining it to the 6-
APA nucleus. This reaction usually takes place in aqueous
phase with a slightly alkaline pH. Subsequently, the 6-APA
is extracted by adjusting the pH to the isoelectric point. The
side chain component is first isolated through a solvent. This
is followed by an additional aqueous-phase extraction, so that
it may be recycled as a precursor in the fermentation itself.
Of course, this has to be done following the appropriate tests.
After all these, we can recover the 6-APA product, which
is present in the crystallization mother liquors, through
concentration by the reverse osmotic process. This is done
at proper concentrations, which make crystallization easier
[34].
4. Six Sigma Methodology: An Overview
4.1. Six Sigma: An Introduction. In statistics, we know that
Sigma (𝜎) is a term that commonly represents standard
deviation which is an indicator of the degree of deviation
in a group of measurements or a process. Six Sigma (6𝜎)
is a statistical perception that assesses a process in terms
of faults or defects (see Table 1). It can be envisioned as
a viewpoint of managing which centers on erasing defects
through practices that stress understanding, measuring, and
betterment processes [43]. Harry (1998) defines Six Sigma to
be “a strategic initiative to boost profitability, increase market
share and improve customer satisfaction through statistical
tools that can lead to breakthrough quantum gains in quality”
[44]. In 1987, Motorola first launched Six Sigma [43] and was
soon followed by some leading electronic companies such as
IBM, DEC, and Texas Instruments in early 1990s. In 1995,
when GE and Allied Signal instigated Six Sigma as planned
initiatives, a fast propagation took place in nonelectronic
farms globally [45].
By detecting and eliminating the reasons of defects
(errors) and minimizing inconsistency in production and
business processes, Six Sigma helps to enhance the quality of
process outputs. It crafts a unique infrastructure of personnel
within the business organization (“Black Belts,” “Green Belts,”
etc.) by employing an array of quality management methods.
Each Six Sigma assignment that is carried out within an
organization follows an established sequence of steps and has
quantified economic targets [46].
4.2. Six Sigma: Principles. Six Sigma projects follow two
project methodologies: DMAIC and DMADV. These have
Table 1: Probability of defects of different Sigma levels at a fixed
process mean reproduced from elsewhere [43].







“ppm”: parts per million.
five phases each and are motivated by Deming’s plan-do-
check-act cycle [47].WhileDMAIC is used for projects aimed
at improving an existing business process, DMADV is used
for projects aimed at creating new product or process designs
[43]. Since in the current study we only deal with devising
a strategy to improve the large-scale existing production of
Penicillin G and its subsequent conversion to 6-APA, we will
consider only DMAIC.
DMAIC (Define-Measure-Analyze-Improve-Control)
process acts as a step forward policy and is probably the
most important methodology in Six Sigma management
[43]. This methodology allows genuine improvements and
genuine results and works identically well on several entities
(variation, cycle time, yield, design, etc.). It is divided into
five phases as shown in Figure 2.
In each phase the major activities are as follows [43].
Phase 0 (Definition).Here we identify the process or product
that has to be improved. We may also standardize the
principal product or process features of other leading global
farms. Phase 1 (Measurement). Here, the product features
such as reliant variables, relevant process mapping, essential
measurement performing, result recording, and short- and
long-term process capability estimating are selected. In iden-
tifying critical product features, quality function deployment
(QFD) plays a significant role. Phase 2 (Analysis). Here
we scrutinize and standardize the principal product/process
performance metrics with different statistical and quality
control tools. A gap analysis often ensues to detect the
regular factors of thriving performance, that is, what factors
explicate best-in-class performance. Phase 3 (Improvement).
Here we identify those product performance features which
have to be advanced to reach the target. This is followed
by detecting the major sources of variation, identification
of the principal process variables (by Taguchi methods and
other vigorous experimental designs), and verification of
the developed orders of principal process variables. Phase 4
(Control).The final phase is commenced by knowing that the
new process conditions are documented and scrutinized via
statistical process control (SPC) methods. Sometimes, it is
wise to revisit one or more of the earlier phases depending
upon the consequence of such a follow-on investigation.
4.3. Six Sigma Approach in Pharmaceutical Industries through
Case Studies. As a part of the current work, it is essential to
be acquainted with the current status of the application of
total quality system for the production of pharmaceuticals,










Figure 2: Improvement phases in the Six Sigma methodology (reproduced and redrawn from elsewhere [43]).
preferably through a few case studies. It is a probability that
the modification of the fermentation unit of the bioprocess
or improvement of operations in downstream processing
may result in the design and optimization advancement of
the pharmaceutical production process [48]. It is found that
quality control strategies (including Six Sigma) as a means
to either improve production or to enhance product quality
in the pharmaceutical industries have been proposed or
predicted through simulations by diverse groups [49–53]. An
early study forecasted a theoretical model for penicillin syn-
thesis, with qualitative prediction of different developments
that are generally countered in experiments and also reviewed
variousmodels for secondarymetabolitemanufacturing [49].
This work was carried forward by Birol et al. [51] where the
authors broadened the model by Bajpai and Reuss [49] and
developed a simulation code for a fed-batch fermenter pro-
ducing penicillin by including several additional parameters
and trying to identify errors in a representative penicillin
fermentation procedure. Both these studies throw some light
on the possibility of minimal deviation from the ideal process
flowchart that could be achieved through accurate modular
predictions. Also, it is critical that any group embarking on
such work comprehends the process well particularly while
choosing correct output variables [52]. This has been shown
by an earlier work where the operating pH and temperature
turned out to be the decisive parameters that affected the
penicillin yield [50].
Case studies that involve integration of Six Sigma
methodology in pharmaceutical production unit have been
conducted in related areas such as biological, parenteral
operations, safety, and improved control of potency [53].
Six Sigma can serve as the driving force for continuous
improvement by identifying the root cause or causes of
low process yield, due to excessive variance in the desired
specifications [52]. It is possible to advance the process
controllability leading to enhanced sigma levels [54]. It has
been proposed that the Six Sigmamethodologymay decrease
discrepancy and focus on significant elements to attain con-
tinuous improvement by identifying and analyzing all of the
constituent steps of prophylactic antibiotic administration
and then observing them for improvement [55]. According
to Nunnally and McConnell [53], the application of Six
Sigma has helped in minimizing deviations in two of the
key variables, pH and specific potency, in a fermentation
set-up. Recently, a very interesting work has focused on an
amalgamation of Six Sigma methodology with incorporated
design and control and has predicted superior yield of
archetypal penicillin [52]. This significant work, which used
a combination of different quality control approaches includ-
ing process analytical technologies (PAT) and Six Sigma
methodology, demonstrated a 40% decrease in batch time,
but simultaneously a considerable enhanced throughput yield
and reduction in the concentration of contaminants. This
facilitated our work which is based on similar motivation,
but we have focused exclusively on Penicillin G and have
extended the approach till its conversion to 6-APA.
5. Proposed Six Sigma Approach for
Production of Penicillin
G and Conversion to 6-APA
We are going to implement the five major principles of Six
Sigma methodology (DMAIC) as indicated in Figure 2 and
explained in Section 4.Wewill start with “DEFINE.” Here the
approach is twofold: (a)DEFINE the process and (b)DEFINE
the business case.
5.1. “DEFINE”
(a) “DEFINE” the Process. The process of acquiring crys-
tallized Penicillin G is represented in Figure 3. Briefly, the
inputs consist of culture medium, inoculum (Penicillium
chrysogenum), and trained personnel required to handle the










Figure 3: Schematic representation of producing crystallized Penicillin G.
operations and for process monitoring. Both fermentation
and downstream processing (recovery and purification) have
been integrated into processes for simplicity of the Six Sigma
approach. The output is the crystallized form of Penicillin G.
(b) “DEFINE” the Business Case. Problem statement: product
quality, safety, consistency, and purity depend on presence
of contaminants. It is important to eliminate the contami-
nants comprehensively. Project goal: improvement of product
quality, safety, consistency, and purity can be addressed by
considering the following key issues: (A) examination of seed
lots for endogenous and adventitiousmicrobial contaminants
(like retroviruses, bacteria, fungi, mycoplasma, etc.), done by
some important tests: (i) reverse transcriptase (RT) assay and
electron microscopy (EM) (for retroviruses), (ii) sterility and
mycoplasma test, in vitro virus test, and genetic, immuno-
logical, and biochemical tests (for bacteria, mycoplasma, and
fungi), and (iii) determination of inherent characteristics
like isoenzyme pattern and chromosomal composition (for
establishing cell identity), and (B) examination of cell and
product stability during the production process.
In the past decade, several studies have stressed upon the
fact that due to their extremely minute physical dimensions
EM remains the preferred choice for visualization of most
viruses (including retroviruses) either in liquid samples or in
infected cells [56–59].Though there have been some concerns
raised over the usefulness of EM [60, 61], particularly when
more sensitive methods such as the PCR and fluorescence
lightmicroscopy are available [57], the credibility of EM (par-
ticularly TEM) remains indispensible for some virological
features, preliminary detection of unidentified viral agents
and increased resolution for distinguishing between viral
protein aggregates and viral particles with distinct structures,
and is thus on the preferred list of regulatory agencies
when inspecting for the viral safety of biological products
[57]. In fact, we believe that inspection of pharmaceutical
samples through a combination of an EM technique and
other techniques like RT-PCR could be most potent for the
identification of desired target. This combinatorial approach
is highly beneficial for the analysis of complex biological
systems (such as those involving retroviruses) because there
ismore data available tomake valid conclusions possible than
it would have been using a single approach [56–58]. Thus,
in order to enforce a stringent quality control system, use
of high-throughput analytical instruments and hyphenated
techniques is necessary, even though this may significantly
raise the expenditure and cost of implementation. While the
authors acknowledge the fact that initial investment costs are
high, especially those pertaining to EM, and research groups
particularly in developing countries could be apprehensive
in this regard, the possibility of enhanced grants from
government agencies in helping procuring the instrument
could be a source of hope.
5.2. “Measure” and “Analyze” the Current Process Performance.
The objective of “Measure” is to identify critical measures
in the penicillin production process that are necessary to
evaluate the success which will meet the requirements of cus-
tomer and to develop amethodology to collect data efficiently
and to measure the process performance [43]. However, the
most important part is to understand the elements of Six
Sigma calculation and establish a threshold value for Sigma
for the upstream, fermentation, and downstream processes.
This is very important since it explains “how we are doing”
all those implementations which we need to do. The main
activities involved in this section are (i) identifying inputs
(inoculums, media, etc.), processes (upstream, fermentation,
and downstream processing), and output (6-APA, Penicillin
G, etc.) indicators, (ii) developing operational definition and
measurement plan, (iii) plotting and analyzing data, (iv)
identifying any special cause, (v) constructing cause and
effect matrix, and (vi) collecting other baseline performance
data. To materialize what we have thought of, we need some
good mold sampling techniques. From these, we may choose
the one or two different techniques that suit best for P.
chrysogenum. Some commonmold sampling techniques [62]
are described below.
5.2.1. Air Sampling. To accumulate particles that are airborne,
we need a tape, cassette, or a gathering device together with
a regulated air pump [62]. Some common air-samplers are
impaction samplers, cassette samplers, cassette-like samplers,
Andersen samplers, and Andersen-type impaction samplers.
Investigating the air may be helpful because of the huge
supply source which has not yet been found in a building.
This may be significant to analyze the relative molecule levels
between an issue territory and a control region or in a
prior zone and then afterward cleaning [62]. A qualitative
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analysis of an air sample by an expert technician can provide
proof of a nearby problem mold reservoir in certain cases,
for example, if the indoor sample contains long chains of
Penicillium spores. Examining particles on a slide to count
mold spores/cubic meter of air, mold spores/square meter
of surface area, or mold CFU (colony-forming units) is a
common practice in building investigations. These measures
can be used to describe the results of some sampling or “mold
testing” methods in the penicillin production plant. If there
are more than 10000 molds present in one cubic meter of air
in a building, the mold contamination is a reality, though this
is not a customary quantitative standard [62].
5.2.2. Tape Sampling. The inspected surface is first pressed
with an agreeable cellophane tape, then evacuated, and
altered to a clean surface for mailing to a lab. The tape is
then readied by the lab for examination under microscope.
The tape may also be extensively analyzed for identifying
the genus and species of a particular mold. This is the
minimum exorbitant gathering system accessible and is a
favoured instrument [62]. In some cases genera determi-
nation alone is quite sufficient as some of the common
problem-genera (Penicillium and Aspergillus spp.) do not
have nonproblematic members that grow in buildings. If
there are large amounts of molds present in a building,
this is just a qualitative technique [62]. Combined with a
visual inspection to locate target areas of risk and to find
visible problems, it is the most essential component of a
buildingmold investigation and is themethod recommended
by experts. When a tape is pressed into a sizeable area of
anticipated mold growth on a surface, it collects majority of
the material. This often includes enough structural material
based on which persistent awkward mold genera and species
may be isolated. When a sample is properly collected, it
will definitely contain some significant tools that may aid in
speciation, like hyphae, conidia, and so forth [62]. In short, we
can say that the determination of the presence of a building
mold problem (toxic or allergenic) versus cosmetic mold can
usually be made from tape samples alone.
5.2.3. Vacuum Sampling. For testing beddings, curtains, and
so forth (which are soft goods) for enhanced levels of
tainted spores, vacuum samples may be a suitable choice as
a qualitative approach, which can be used as an inspection
method for mold clearance. A vacuum or an air pump may
be attached to a collection canister through which particles
may be drawn onto the surface of the filter or into some
particular gathering storage place [62]. The main R&D lab
clears the filter onto a microscope slide, washes the filter
onto a microscope slide, or uses another method to transfer
particles for examination by microscope for preparation by
culture.
5.2.4. Swab Sampling. This is a good choice for microscopic
inspection of the particles but may kill the identified hyphae
and conidiophores [62]. We have to make use of swabs
to sample for bacteriological contamination. Two principal
ways of swab processing are either by culturing (the swab
is rolled across a culture plate for culturing and subsequent
sample detection) or by a direct examination (similar to tape
sampling explained above) [62]. Please note that techniques
such as amplification through polymerase chain reaction or
PCR may also be tried for the detection of individual species
and/or genus with superior precision and fairly rapidly. The
method requires costly equipment and is not available atmost
laboratories. Perhaps more important is that the database
of PCR identification information is limited to a small set
of species compared with the wide range of genera/species
which normally occur. The most commonly used seed lot
system involves one 100–200 vialmaster cell bank (MCB) and
one or more 400–500 vial manufacturer’s working cell banks
(MWCB) derived from the MCB. While the adventitious
agents, such as mycoplasma, viruses, and prions can be ini-
tiated during the handling procedure or may be added by the
parental cells and nutrients and can be identified via specific
tests such as sterility andmycoplasma tests, the contaminants
of bacterial origin are usually identified by cell substrate
inoculation in suitable microbial media and incubating for
2–4 weeks followed by biochemical tests and microscopic
examination [63]. Mycoplasma is detected by DNA staining
or immunological tests. Inoculum stability is alsomeasured at
three levels: (i) during the storage of cell banks, (ii) through
several cell divisions in each production batch, and (iii)
during various production batches. Suspension systems, such
as stirred tank or airlift reactors, and entrapped systems, such
as fluidized bed or hollow fiber reactors, are commonly used
for Penicillin G production. Stirred tank and airlift reactors
can operate in batch and fed-batch mode.
5.3. “Improve” the Process
(A) In-Process Testing. In-process testing must be done at 3
different stages.They are (i) testing of samples collected at the
preculture (inoculum) step, (ii) testing of samples collected at
specific intervals during the large-scale cultivation process,
and (iii) testing of samples collected at the end of the
bioreactor run.The technique is essential to distinguish novel
or triggered foreign agents. There must be a methodical
exploration in order to resolve the cause of contamination
andwidespread decontamination of the bioreactor and all the
affected areas are recommended. Also, the entire analysis and
decontamination actions must be properly documented and
preserved.
(B) Culture Stability Testing. Factors such as specific pro-
ductivity (pg/cell/day), cell growth kinetics, and the portion
of producer cells in the cell bank (clonality) may assist in
scrutinizing the similarity between theMCBandMWCB.The
manufacturing process may witness the subsequent stage of
cell line stability tests being performed, for which the cells are
assembled from initial, middle, and terminal phases of the
cultivation cycle [63]. For example, in a batch process, cells
are collected from the preculture, inoculum, and three times
during production: the lag phase, the exponential growth
phase, and at the end of production.
5.4. “Controls” to Hold the Gains. Several sophisticated supe-
rvising and organizing strategies, for instance, optical density
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probes and image analysis attached to some superior controls
system have been applied in small-scale fermentation [63].
However, these advanced strategies are at most cautiously
applied in large-scale fermentation processes. Production
processes typically utilize online control for pH, temperature,
and dissolved oxygen only. Batch cultures often require little
to no additional monitoring and control other than frequent
offline measurements of cell density and viability [43]. Fed-
batch cultures require control of nutrient feed rates. Control
strategies based on cell growth estimates, online oxygen
utilization rates (OUR), or glucose and lactate measurements
have been applied. However, it is a common observation that,
in large-scale processes, the rates for addition of nutrients are
more often based on time generated proceedings and utilize
the control for feedback less frequently [63]. Process valida-
tion demonstrates that the production process performs as
intended in a consistent manner. It must be demonstrated
that the purification process will remove known impurities
such as DNA and medium components. The information
for approval is ordinarily assembled by studying full-scale
assembling runs and likewise by “challenge” studies utilizing
model viruses, DNA, and process contaminants on scaled-
down variants of full-scale process. The itemized dissection
of a little number of full-scale assembling runs can give
immediate confirmation that the refinement procedure can
reliably evacuate known polluting influences for which deli-
cate examinations exist [63].
6. Conclusions
Though the entire study is hypothetical, we have been able
to identify some critical points which may act as potential
sites for integrating the Six Sigma methodology. First the
process and the business case need to be defined separately
which could be trailed by investigation of the seed lots and
the cell or culture stability. Process characterization follows
as an integral part of measure and analysis. All the potential
adventitious agents must be identified using scientific tests
and provisions must be included to get rid of them. All the
fermentation parameters may be optimized at this point.
Also, process improvement needs constant attention by in-
process testing and inspection of the culture stability. This
is followed by validation. It is critical therefore that the
process works as intended for an infinite period. We have
also considered several strategies for process validation and
tried to correlate “DMAIC” with respect to Penicillin G
production. It is our understanding that Six Sigma can be
effectively used as a part of total quality system for the mass
production of Penicillin G and its subsequent conversion to
6-APA.
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